PTGER4 and neoplasm: In this report, we evaluated myeloid cell-modifying effects of EP4 antagonism in vitro and in vivo, examined pharmacologically the concurrent targeting of EP4 signaling and Treg viability in tumor-bearing immunocompetent mice, and investigated the mechanisms driving the combined anti-tumor activity of these agents through a combination of genetic, molecular and cellular phenotypic analyses.